Skip to main content

Table 2 Characteristics of patients with inadequate response to treatment or relapse

From: Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study

Pt Age HAQ at t0 Months of treatment/withdrawal DMARD/mean GC oral dose (mg/d) Previous treatment PCR/CCR (months
to event)
Persisting clinical symptoms PLR/CLR (months
to event)
Persisting biological
activity
Relapse (months to event)
1 24 3 3/drug toxicity CyA/16 GC PCR (1) Arthralgias PLR (1) ↑ WBC,
↑ Ferritin,
↑ Liver enzymes
No
2 16 1.25 6/disease flare MTX/8 MTX+GC
+ETN
PCR (1) Fever, Arthritis PLR (1) Anemia,
↑ WBC,
↑ PLTs,
↑ CRP,
↑ ESR,
↑ Ferritin
Yes (4)
3 56 2.5 3/drug toxicity None/0 GC PCR (0.01) Arthralgias PLR (1) Anemia,
↑ Ferritin
No
4 64 1.5 1.5/drug toxicity LEF/3 MTX+GC CCR (1) - PLR (1) Anemia,
↑ ESR
No
5 48 2.5 14/follow up end MTX for the last 8 months/18.25 GC PCR (0.5)/CCR (8) Arthralgias/Arthritis PLR (1)/CLR (9) ↑ WBC,
↑ CRP
Yes (5)
6 32 1.8 4/no response MTX/4 MTX+GC
+ETN, then ADA
No response Arthralgias/Arthritis No response Anemia,
↑ WBC,
↑ PLTs,
↑ CRP,
↑ ESR,
↑ Ferritin
-
7 49 3 15/follow up end MTX for the last 2 months/18.6 GC CCR (0.2 and 13.5) - CLR (1 and 14) - Yes (13 e.g. 4 months after reducing anakinra dosing)
  1. ADA, adalimumab; CCR, complete clinical response; CLR, complete laboratory response; CRP, C-reactive protein; CyA, cyclosporine A; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; F, female; GC, glucocorticosteroids; HAQ, health assessment questionnaire; LEF, leflunomide; M, male; MTX, methotrexate; PCR, partial clinical response; PLR, partial laboratory response; PLTs, platelets; WBC, white blood cells.